Migraine. Migraine without aura [common migraine], Migraine with aura [classical migraine]
Conditions
Interventions
Intervention 1: Intervention group will receive daily two 200 mg capsule of Coenzyme Q10 with meal for three months besides their usual treatments. Intervention 2: control group will receive daily two
Prevention
Placebo
Intervention group will receive daily two 200 mg capsule of Coenzyme Q10 with meal for three months besides their usual treatments
control group will receive daily two capsule of placebol for three months besides their usual treatments
Sponsors
Vice Chancellor for research of Tabriz University of Medical Sciences - Nutrition Research Center
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: inclusion criteria: Female; patient tendency and ability to participate in the study; age between 18-50; a definitive diagnosis of migraine based on IHS criteria; headache history for at least one year; episodic migraine with or without aura; having at least two headaches per month. Exclusion criteria: Menopause; suffering from tension type or other headaches; having chronic disease (such as diabetes, cardiovascular disease, chronic kidney disorders and functional liver disorders and cancers); having history of stroke or MI; smoking; pregnancy or intend to pregnancy or lactation; using CO-Q10 during the last three month before study; daily or almost daily using(>15/month) of narcotics; using antioxidant supplements; consuming anti-hypertention and anti-hyperlipidemia drugs.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Migriane frequency. Timepoint: at the baseline, 6 and 12 weeks after the intervention. Method of measurement: questionnaire.;Migraine severity. Timepoint: at the baseline, 6 and 12 weeks after the intervention. Method of measurement: questionnaire.;Migraine duration. Timepoint: at the baseline, 6 and 12 weeks after the intervention. Method of measurement: questionnaire.;CGRP Neuropeptide. Timepoint: at the baselinen and 12 weeks after the intervention. Method of measurement: ELISA kit.;TNF-a. Timepoint: at the baseline and 12 weeks after the intervention. Method of measurement: ELISA kit.;IN-6. Timepoint: at the baseline and 12 weeks after the intervention. Method of measurement: ELISA kit.;IL-10. Timepoint: at the baseline and 12 weeks after the intervention. Method of measurement: ELISA kit.;TAC. Timepoint: at the baseline and 12 weeks after the intervention. Method of measurement: spectrophotometry.;MDA. Timepoint: at the baseline and 12 weeks after the intervention. Method of measurement: TBA (Thio Barbituric Acid).;Triglyceride(TG). Timepoint: at the baseline and 12 weeks after the intervention. Method of measurement: enzymatic method.;Total cholesterol (TC). Timepoint: at the baseline and 12 weeks after the intervention. Method of measurement: anzymatic method.;High density lipoprotein cholesterol (HDL-c). Timepoint: at the baseline and 12 weeks after the intervention. Method of measurement: anzymatic method.;Low density lipoprotein cholesterol (LDL-c). Timepoint: at the baseline and 12 weeks after the intervention. Method of measurement: Friedewald Equation.;Serum Co-Q10 levels. Timepoint: at the baseline and 12 weeks after the intervention. Method of measurement: HPLC.;Dietary intake. Timepoint: at the baseline, 6 and 12 weeks after the intervention. Method of measurement: 3 days food record.;Anthropometric measurements. Timepoint: at the baseline, 6 and 12 weeks after the intervention. Method of measurement: BMI, waist circumference and body fat percent.;Ad | — |
Secondary
| Measure | Time frame |
|---|---|
| Physical activity. Timepoint: at the baseline, 6 and 12 weeks after the intervention. Method of measurement: IPAQ questionnaire. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed